°øÁö : µµÄìÁõ±Ç°Å·¡¼Ò JASDAQ ½ºÅÄ´Ùµå ½ÃÀå ½Å±Ô »óÀå °ü·Ã ¾È³»

Global Information
ȸ»ç¼Ò°³ | ¹®ÀÇ | ºñ±³¸®½ºÆ®

À¯·´ÀÇ ÀǾàǰ ¹× ÇコÄÉ¾î »ê¾÷(ºÐ±âº° °»½Å º¸°í¼­)

Europe Pharmaceuticals & Healthcare

¸®¼­Ä¡»ç Fitch Solutions, Inc.
¹ßÇàÁ¤º¸ ¿¬°£±¸µ¶ »óǰ ÄÚµå 363589
ÆäÀÌÁö Á¤º¸ ¿µ¹® 50 Pages
°¡°Ý
US $ 1,415 £Ü 1,615,000 PDF (Single user license) - Includes 3 FREE quarterly updates


À¯·´ÀÇ ÀǾàǰ ¹× ÇコÄÉ¾î »ê¾÷(ºÐ±âº° °»½Å º¸°í¼­) Europe Pharmaceuticals & Healthcare
¹ßÇàÁ¤º¸ : ÆäÀÌÁö Á¤º¸ : ¿µ¹® 50 Pages

¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹®¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹®¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

À¯·´ ±¹°¡ÀÇ ÀǾàǰ(Pharmaceuticals) ¹× ÇコÄɾî(Healthcare) »ê¾÷¿¡ ´ëÇØ ºÐ¼®ÇßÀ¸¸ç, Áö¿ª ÀüüÀÇ »ê¾÷ ±Ô¸ð ½ÇÀû°ú ¿¹Ãø(°ú°Å 5³â°£, ÇâÈÄ 10³â°£), ¾÷°è°¡ ¾È°í ÀÖ´Â °úÁ¦(À§Çè)°ú ÇâÈÄ ¸ÅÃâ ±âȸ(º¸»ó)¿¡ °üÇÑ Æò°¡, Áö¿ª³» °¢ Áö¿ª »ó¼¼ µ¿Çâ, ÁÖ¿ä ±â¾÷ °³¿ä µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.

1. BMIÀÇ »ê¾÷ ºÐ¼®

  • À¯·´ ½ÃÀåÀÇ ÃֽŠ»óȲ

2. SWOT ºÐ¼®

  • À¯·´ ½ÃÀåÀÇ ÃֽŠ»óȲ

3. »ê¾÷ ¿¹Ãø

  • ÀǾàǰ ½ÃÀåÀÇ ÃֽŠ»óȲ
  • ÇコÄÉ¾î ½ÃÀåÀÇ ÃֽŠ»óȲ

4. »ê¾÷ À§Çè/º¸»ó ÁöÇ¥

  • À¯·´ : À§Çè/º¸»ó ÁöÇ¥

5. ½ÃÀå °³¿ä

  • À¯·´ ½ÃÀåÀÇ ÃֽŠ»óȲ

6. ¾÷°è µ¿Çâ°ú ¹ßÀü

  • À¯·´ ½ÃÀåÀÇ ÃֽŠ»óȲ

7. Áö¿ª ½ÃÀå °³¿ä

  • À¯·´ ½ÃÀåÀÇ ÃֽŠ»óȲ

8. ¿ë¾îÁý

9. ºÐ¼® ¹æ¹ý

  • ÀǾàǰ ÁöÃâ¾× ¿¹Ãø ¸ðµ¨
  • ÀÇ·áºñ ¿¹Ãø ¸ðµ¨
  • ºÐ¼® ¹æ¹ý¿¡ °üÇÑ ÁÖ¼®
  • À§Çè/º¸»ó ÁöÇ¥ ¹æ¹ý
  • ÁöÇ¥ÀÇ °³¿ä
  • ÁöÇ¥ÀÇ °¡ÁßÄ¡
KSM 16.08.08

Key View: The Europe region will continue to attract significant investment from multinational pharmaceutical firms, although drugmakers will find different opportunities in the Western and emerging Europe sub-regions due to region-specific trends. The more developed Western markets will continue to be favoured by innovative drugmakers due to stronger regulatory oversight and greater purchasing power, although growth in these markets will be suppressed by aggressive cost-containment. Revenue growth potential is significant in emerging Europe due to the expansion of healthcare access; however, the majority of growth will be driven by generic drug sales. We note that the Covid-19 pandemic has affected all countries in the region driving upwards revisions to our forecasts for healthcare spending as health authorities undertake extraordinary measures at short notice such as establishing emergency hospitals. Over the full year 2020, we expect Covid-19 to have the opposite effect on pharmaceutical sales as new drug launches are postponed and fewer non-Covid-19 hospital and doctor visits result in fewer prescriptions.

Table of Contents

  • Key View
  • SWOT
  • Industry Forecast
  • Pharmaceutical Market Forecast
  • Healthcare Market Forecast
  • Industry Risk/Reward Index
  • Western Europe Innovative Pharmaceuticals Risk/Reward Index
  • Central And Eastern Europe Innovative Pharmaceuticals Risk/Reward Index
  • Market Overview
  • Industry Trend Analysis
  • Central And Eastern Europe Pharmaceuticals & Healthcare Theme
  • Europe Pharmaceuticals & Healthcare Theme
  • Western Europe Pharmaceuticals & Healthcare Theme
  • Industry Trends And Developments
  • Europe Pharmaceuticals & Healthcare Q320 Round-Up
  • Pharmaceuticals & Healthcare Glossary
  • Pharmaceuticals & Healthcare Methodology
Back to Top
ÀüÈ­ ¹®ÀÇ
F A Q